ZINC ASPARTATE

First approved in 2019

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C4H5NO4.Zn.2H
Molecular Weight	329.598
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H+].[H+].[Zn++].N[C@@H](CC([O-])=O)C([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O

InChI

InChIKey=POEVDIARYKIEGF-CEOVSRFSSA-L

InChI=1S/2C4H7NO4.Zn/c2*5-2(4(8)9)1-3(6)7;/h2*2H,1,5H2,(H,6,7)(H,8,9);/q;;+2/p-2/t2*2-;/m00./s1

HIDE SMILES / InChI

Molecular Formula	C4H6NO4
Molecular Weight	132.0947
Charge	-1
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Zn
Molecular Weight	65.409
Charge	2
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.farmapol.pl/en/produkty/Non_prescription_medicines/189,zincas.html | https://www.ncbi.nlm.nih.gov/pubmed/25146336

Zinc aspartate is an approved drug, used to treat zinc deficiency in humans. Zinc aspartate regulates the production of the growth hormone and sex hormones (it is necessary for the production of sperm cells and egg cells). It reduces the body’s susceptibility to infections and allergies. It promotes the proper secretion of insulin by the pancreas. Zinc deficiency causes: disorders in the functioning of the skin, the digestive system, the nervous system, the immunological system, and the skeletal system. Significant zinc deficiency can cause dwarfism and genital underdevelopment. Zinc aspartate suppresses experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis (MS), as well as effector T cell functions in vitro.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
T cell activation involved in immune response 1 Target ID: GO:0002286 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22350510	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Multiple sclerosis 107 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25146336 https://www.ncbi.nlm.nih.gov/pubmed/22350510	Primary	Preclinical	Unknown Approved Use Unknown
Myringosclerosis 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19961406	Preventing	Preclinical	Unknown Approved Use Unknown
Ischemia-reperfusion injury 7 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19937281 https://www.ncbi.nlm.nih.gov/pubmed/17112542	Primary	Preclinical	Unknown Approved Use Unknown
Zinc deficiency 39 Sources: http://www.farmapol.pl/en/produkty/Non_prescription_medicines/189,zincas.html https://www.ncbi.nlm.nih.gov/pubmed/3924542	Primary	Approved 8583	Zincas Approved Use Indications for use: complementation of zinc deficiency in the body
Acrodermatitis enteropathica 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1179792	Palliative	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Oral zinc aspartate treats experimental autoimmune encephalomyelitis.	2014-12	25146336
Zinc and propolis reduces cytotoxicity and proliferation in skin fibroblast cell culture: total polyphenol content and antioxidant capacity of propolis.	2014-07	24913100
Congenital diseases of the gastrointestinal tract.	2014-05	24940857
Further studies on selective radioprotection by organic zinc salts and synergism of zinc aspartate with WR 2721.	1990-06	2165842
Differential radioprotection of bone marrow and tumour cells by zinc aspartate.	1988-06	3370431
Synergism of organic zinc salts and sulfhydryl compounds (thiols) in the protection of mice against acute ethanol toxicity, and protective effects of various metal salts.	1987-06	3630856
Effect of oral zinc application during pregnancy.	1986	3710284

Patents

Sample Use Guides

In Vivo Use Guide

For inflammatory bowel disease, 300 milligrams of zinc aspartate (equal to 60 milligrams of elemental zinc) has been taken by mouth daily for four weeks.

Route of Administration: Oral

In Vitro Use Guide

Zinc aspartate, at a concentration of 16 uM, increased human fibroblasts proliferation in cell culture

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:17:00 GMT 2025` Edited by `admin` on `Mon Mar 31 18:17:00 GMT 2025`
Record UNII	4OC7QTI23H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZINC ASPARTATE

Official Name

English

ASPARTATE ZINC

Preferred Name

English

Aspartate zinc [WHO-DD]

Common Name

English

ZINCATE(2-), BIS(L-ASPARTATO(2-)-.KAPPA.N,.KAPPA.O1)-, HYDROGEN (1:2), (T-4)-

Common Name

English

ZINCATE(2-), BIS(L-ASPARTATO(2-)-N,O(SUP 1))-, DIHYDROGEN, (T-4)-

Common Name

English

DIHYDROGEN BIS(L-ASPARTATO(2-)-N,O1)ZINCATE(2-)

Common Name

English

Classification Tree Code System Code

DSLD

137 (Number of products:9660)